Lv1
10 积分 2025-06-07 加入
Long-term Efficacy of Vedolizumab for Crohn’s Disease
1天前
已完结
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
1天前
已完结
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
2天前
已完结
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
2天前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
5天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
5天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
5天前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
1个月前
已关闭
Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma
1个月前
已完结
皖公网安备34019202002308
